Targeting kras in metastatic colorectal cancer: Current strategies and emerging opportunities

Manuela Porru, Luca Pompili, Carla Caruso, Annamaria Biroccio, Carlo Leonetti

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge for cancer research. In this review, we highlight the emerging experimental strategies for blocking KRAS function and signaling and its direct targeting. We also report on the results in this field of research produced by our group.

Original languageEnglish
Article number57
JournalJournal of Experimental and Clinical Cancer Research
Volume37
Issue number1
DOIs
Publication statusPublished - Mar 13 2018

Fingerprint

Oncogenes
Colorectal Neoplasms
Research
Neoplasms
Pharmacology
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{439197a89a4d4b72b0cfa5156458d137,
title = "Targeting kras in metastatic colorectal cancer: Current strategies and emerging opportunities",
abstract = "Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge for cancer research. In this review, we highlight the emerging experimental strategies for blocking KRAS function and signaling and its direct targeting. We also report on the results in this field of research produced by our group.",
author = "Manuela Porru and Luca Pompili and Carla Caruso and Annamaria Biroccio and Carlo Leonetti",
year = "2018",
month = "3",
day = "13",
doi = "10.1186/s13046-018-0719-1",
language = "English",
volume = "37",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Targeting kras in metastatic colorectal cancer

T2 - Current strategies and emerging opportunities

AU - Porru, Manuela

AU - Pompili, Luca

AU - Caruso, Carla

AU - Biroccio, Annamaria

AU - Leonetti, Carlo

PY - 2018/3/13

Y1 - 2018/3/13

N2 - Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge for cancer research. In this review, we highlight the emerging experimental strategies for blocking KRAS function and signaling and its direct targeting. We also report on the results in this field of research produced by our group.

AB - Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge for cancer research. In this review, we highlight the emerging experimental strategies for blocking KRAS function and signaling and its direct targeting. We also report on the results in this field of research produced by our group.

UR - http://www.scopus.com/inward/record.url?scp=85043602156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043602156&partnerID=8YFLogxK

U2 - 10.1186/s13046-018-0719-1

DO - 10.1186/s13046-018-0719-1

M3 - Article

AN - SCOPUS:85043602156

VL - 37

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

M1 - 57

ER -